India, July 6 -- This partnership is more than a routine distribution agreement. It enables Zydus to enter India's underpenetrated early cancer screening market through an asset-light model. By combining Guardant Health's advanced screening technology, Apollo Hospitals' nationwide network, and Zydus' oncology expertise, the company is strengthening its long-term position in the fast-growing precision diagnostics segment.

Zydus Lifesciences Limited is currently trading at Rs 1,150. The stock opened at Rs 1,145, reached a day's high of Rs 1,151.9, and has so far recorded a day's low of Rs 1,131.6. The current market capitalisation of the company is Rs 1,15,264 crore, and it is trading at a P/E ratio of 21.2, which is lower than the industr...